<DOC>
	<DOCNO>NCT02902432</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety recombinant human endostatin（continuously-pumped）combined chemoradiotherapy patient advance squamous cell carcinoma head neck . The patient randomize concurrent radiotherapy ( CRT ) arm CRT + Endostar arm . All patient receive one cycle induction chemotherapy , intensity modulate radiation therapy ( IMRT ) weekly cisplatin 3 cycle chemotherapy IMRT . Treatment cycle repeat every 21 day maximum 4 cycle . In CRT + Endostar arm , Endostar continuously intravenous pumped ( 7.5 mg/m2 ) 14 day ( d1-d14 ) chemotherapy 5 days/week ( d-5-d-1 , d3-d7 , d10-d14 , d17-d21 ) IMRT .</brief_summary>
	<brief_title>A Trial Endostar Patients With Carcinoma Head Neck</brief_title>
	<detailed_description>The patient randomize CRT arm CRT + Endostar arm . All patient receive one cycle induction chemotherapy , intensity modulate radiation therapy ( IMRT ) weekly cisplatin 3 cycle chemotherapy IMRT . Treatment cycle repeat every 21 day maximum 4 cycle . In CRT + Endostar arm , Endostar continuously intravenous pumped ( 7.5 mg/m2 ) 14 day ( d1-d14 ) chemotherapy 5 days/week ( d-5-d-1 , d3-d7 , d10-d14 , d17-d21 ) IMRT . Prior enrollment study patient receive therapy , routine test , ECG , head neck CT scan MRI perform check body 's response treatment . Further , treatment , circulate endothelial cell ( CECs ) , endothelial progenitor cell ( CEPs ) , vascular endothelial growth factor ( VEGF ) , Cancer embryo antigen ( CEA ) , Neuron-specific enolase ( NSE ) blood Microvessel density ( MVD ) , hypoxia-inducible factor-1a ( HIF-1a ) , P53 , VEGF , Survivin pathological specimen test . Patients progressive disease intolerable side effect remove study . Patients stable disease tumor response continue therapy maximum 4 cycle . Primary outcome : The response rate ( RR ) , clinical benefit rate ( CBR ) , time tumor progression ( TTP ) . Secondary outcome : The quality life ( QOL ) ，Safety Tolerability .</detailed_description>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Histologically confirm unrespectable postoperative recurrent squamous cell carcinoma head neck ; No prior radiation chemotherapy biotherapy ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1.Life expectancy great 3 month ; Patients must adequate bone marrow function : Platelets ≥ 80×109/L Hemoglobin ≥100 g/L Absolute NeutrophilCount ≥1.5×109/L white blood cell≥ 3.5×109/L Patients must adequate liver renal function : Aspartate aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) &lt; 2.5 × upper limit normal Alkaline phosphatase &lt; 2.5 × upper limit normal Total bilirubin &lt; 1.5 mg/dL Creatinine &lt; 1.5 mg/dL× upper limit normal A cardiac ejection fraction ＞ 50 % ; Ability understand willingness sign write informed consent . Participation investigational drug study within 4 week precede start study treatment ; Age ≤18 ≥75 year Age ; Pregnant breastfeed woman ; Serious , uncontrolled , concurrent infection ( ) require antibiotic ; Clinically apparent central nervous system metastases carcinomatous meningitis ; Treatment carcinoma within last 3 month ; Patient unable willing perform study related biopsy blood draw exploratory endpoint enrol study study relate procedure mandatory ; Patients clinically significant cardiac disease ( New York Heart Association Classification III IV cardiac arrhythmia well controlled medication ) , myocardial infarction within previous six month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>endostar</keyword>
	<keyword>cisplatin</keyword>
</DOC>